Concepts (218)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Buprenorphine | 10 | 2026 | 199 | 4.520 |
Why?
|
| Opioid-Related Disorders | 14 | 2026 | 531 | 4.380 |
Why?
|
| Opiate Substitution Treatment | 10 | 2026 | 225 | 2.860 |
Why?
|
| Telemedicine | 3 | 2026 | 376 | 1.760 |
Why?
|
| Dermatitis, Atopic | 7 | 2026 | 31 | 1.390 |
Why?
|
| Eczema | 6 | 2023 | 9 | 1.170 |
Why?
|
| Hypertension | 3 | 2023 | 616 | 1.130 |
Why?
|
| Narcotic Antagonists | 4 | 2025 | 133 | 1.050 |
Why?
|
| Ischemic Attack, Transient | 2 | 2017 | 96 | 0.960 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2024 | 126 | 0.890 |
Why?
|
| Antihypertensive Agents | 2 | 2015 | 183 | 0.790 |
Why?
|
| Stroke | 3 | 2017 | 1221 | 0.770 |
Why?
|
| Asthma | 5 | 2023 | 485 | 0.690 |
Why?
|
| Drug Overdose | 1 | 2023 | 123 | 0.680 |
Why?
|
| Smoking Cessation | 7 | 2022 | 553 | 0.680 |
Why?
|
| Mobile Applications | 1 | 2022 | 142 | 0.640 |
Why?
|
| Humans | 46 | 2026 | 65645 | 0.600 |
Why?
|
| Health Promotion | 2 | 2015 | 523 | 0.580 |
Why?
|
| Quality Indicators, Health Care | 2 | 2019 | 348 | 0.560 |
Why?
|
| Prisons | 6 | 2022 | 121 | 0.540 |
Why?
|
| Family Practice | 2 | 2017 | 215 | 0.520 |
Why?
|
| General Practice | 1 | 2017 | 16 | 0.520 |
Why?
|
| Dental Care | 1 | 2017 | 7 | 0.520 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2018 | 104 | 0.520 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2018 | 84 | 0.510 |
Why?
|
| Health Information Systems | 1 | 2017 | 2 | 0.510 |
Why?
|
| General Practitioners | 1 | 2017 | 14 | 0.510 |
Why?
|
| Hepatitis C, Chronic | 1 | 2018 | 89 | 0.510 |
Why?
|
| Secondary Prevention | 2 | 2017 | 165 | 0.510 |
Why?
|
| Continuity of Patient Care | 2 | 2018 | 175 | 0.490 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 464 | 0.480 |
Why?
|
| Smoking Prevention | 4 | 2013 | 163 | 0.480 |
Why?
|
| Oral Health | 1 | 2017 | 67 | 0.480 |
Why?
|
| Aspirin | 1 | 2017 | 172 | 0.470 |
Why?
|
| Information Dissemination | 1 | 2017 | 114 | 0.470 |
Why?
|
| Fentanyl | 4 | 2025 | 67 | 0.470 |
Why?
|
| Medical Records | 1 | 2016 | 140 | 0.460 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2017 | 235 | 0.450 |
Why?
|
| Antiviral Agents | 1 | 2018 | 328 | 0.450 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 137 | 0.440 |
Why?
|
| Documentation | 1 | 2016 | 135 | 0.440 |
Why?
|
| Prisoners | 5 | 2015 | 180 | 0.430 |
Why?
|
| Healthcare Disparities | 2 | 2017 | 409 | 0.400 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 439 | 0.380 |
Why?
|
| Adult | 16 | 2026 | 17511 | 0.370 |
Why?
|
| Hypersensitivity | 2 | 2023 | 73 | 0.370 |
Why?
|
| Male | 18 | 2026 | 31292 | 0.340 |
Why?
|
| Smoking | 6 | 2022 | 863 | 0.330 |
Why?
|
| Lung Diseases | 1 | 2012 | 183 | 0.330 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 872 | 0.260 |
Why?
|
| Patient Preference | 3 | 2025 | 87 | 0.260 |
Why?
|
| Female | 16 | 2026 | 34309 | 0.260 |
Why?
|
| Patient-Centered Care | 3 | 2018 | 267 | 0.250 |
Why?
|
| Longitudinal Studies | 3 | 2024 | 1288 | 0.250 |
Why?
|
| Histamine Antagonists | 1 | 2026 | 8 | 0.250 |
Why?
|
| Histamine H1 Antagonists | 1 | 2026 | 11 | 0.250 |
Why?
|
| Middle Aged | 8 | 2026 | 18439 | 0.240 |
Why?
|
| Quality Assurance, Health Care | 2 | 2019 | 253 | 0.230 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2025 | 770 | 0.230 |
Why?
|
| Washington | 1 | 2024 | 24 | 0.220 |
Why?
|
| Anesthetics, Dissociative | 1 | 2024 | 7 | 0.220 |
Why?
|
| Oregon | 1 | 2024 | 19 | 0.220 |
Why?
|
| Students, Medical | 2 | 2025 | 268 | 0.210 |
Why?
|
| Smoke-Free Policy | 2 | 2015 | 9 | 0.210 |
Why?
|
| Primary Health Care | 3 | 2021 | 725 | 0.210 |
Why?
|
| Ketamine | 1 | 2024 | 39 | 0.210 |
Why?
|
| Severity of Illness Index | 3 | 2026 | 1567 | 0.210 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2023 | 20 | 0.200 |
Why?
|
| Dermatologic Agents | 1 | 2023 | 22 | 0.200 |
Why?
|
| Students, Nursing | 1 | 2025 | 100 | 0.190 |
Why?
|
| Sublingual Immunotherapy | 1 | 2022 | 1 | 0.190 |
Why?
|
| Patient Participation | 1 | 2025 | 239 | 0.190 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 1 | 2022 | 26 | 0.190 |
Why?
|
| Drug Therapy, Combination | 2 | 2026 | 463 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 741 | 0.180 |
Why?
|
| Naloxone | 1 | 2022 | 53 | 0.180 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2022 | 47 | 0.180 |
Why?
|
| Social Stigma | 1 | 2022 | 79 | 0.170 |
Why?
|
| Tobacco Products | 1 | 2022 | 63 | 0.170 |
Why?
|
| Analgesics, Opioid | 2 | 2025 | 530 | 0.170 |
Why?
|
| Smartphone | 1 | 2022 | 75 | 0.170 |
Why?
|
| Attitude of Health Personnel | 2 | 2025 | 631 | 0.160 |
Why?
|
| United States | 7 | 2023 | 8166 | 0.160 |
Why?
|
| Young Adult | 3 | 2022 | 4855 | 0.160 |
Why?
|
| Pruritus | 3 | 2026 | 32 | 0.150 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2018 | 11 | 0.140 |
Why?
|
| Central Nervous System Agents | 1 | 2018 | 11 | 0.140 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 44 | 0.140 |
Why?
|
| Substance Abuse Detection | 1 | 2018 | 39 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2026 | 809 | 0.140 |
Why?
|
| Systems Integration | 1 | 2018 | 26 | 0.140 |
Why?
|
| Cohort Studies | 1 | 2024 | 2639 | 0.140 |
Why?
|
| Benzodiazepines | 1 | 2018 | 107 | 0.140 |
Why?
|
| Osteoarthritis, Knee | 1 | 2023 | 401 | 0.130 |
Why?
|
| Knowledge Bases | 1 | 2017 | 6 | 0.130 |
Why?
|
| Survival Rate | 1 | 2019 | 847 | 0.130 |
Why?
|
| Epidemics | 1 | 2017 | 27 | 0.130 |
Why?
|
| Patient Compliance | 1 | 2019 | 370 | 0.120 |
Why?
|
| Motivation | 2 | 2022 | 298 | 0.120 |
Why?
|
| Health Information Management | 1 | 2016 | 1 | 0.120 |
Why?
|
| Cotinine | 2 | 2013 | 20 | 0.120 |
Why?
|
| Recurrence | 1 | 2018 | 664 | 0.120 |
Why?
|
| Clinical Medicine | 1 | 2016 | 16 | 0.120 |
Why?
|
| Physician-Patient Relations | 2 | 2018 | 429 | 0.120 |
Why?
|
| Medical History Taking | 1 | 2016 | 65 | 0.120 |
Why?
|
| Counseling | 1 | 2018 | 376 | 0.120 |
Why?
|
| Efficiency, Organizational | 1 | 2016 | 98 | 0.110 |
Why?
|
| Workload | 1 | 2016 | 133 | 0.110 |
Why?
|
| Homicide | 1 | 2015 | 31 | 0.110 |
Why?
|
| Poverty | 1 | 2017 | 307 | 0.110 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2017 | 142 | 0.110 |
Why?
|
| Hyperglycemia | 1 | 2015 | 109 | 0.110 |
Why?
|
| Blood Pressure Determination | 1 | 2014 | 40 | 0.110 |
Why?
|
| Physicians, Primary Care | 1 | 2015 | 79 | 0.100 |
Why?
|
| Retrospective Studies | 1 | 2026 | 6948 | 0.100 |
Why?
|
| Reference Values | 1 | 2014 | 328 | 0.100 |
Why?
|
| Burnout, Professional | 1 | 2016 | 145 | 0.100 |
Why?
|
| Family Health | 1 | 2014 | 68 | 0.100 |
Why?
|
| Disease Management | 1 | 2015 | 235 | 0.100 |
Why?
|
| Violence | 1 | 2015 | 171 | 0.100 |
Why?
|
| Personal Autonomy | 1 | 2013 | 71 | 0.100 |
Why?
|
| Motivational Interviewing | 1 | 2013 | 49 | 0.090 |
Why?
|
| Mass Screening | 1 | 2018 | 700 | 0.090 |
Why?
|
| Blood Pressure | 1 | 2014 | 535 | 0.090 |
Why?
|
| Quality of Life | 3 | 2023 | 1265 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 603 | 0.090 |
Why?
|
| Emergencies | 1 | 2012 | 124 | 0.090 |
Why?
|
| Health Status | 1 | 2014 | 448 | 0.080 |
Why?
|
| Physicians | 1 | 2017 | 486 | 0.080 |
Why?
|
| Skin Diseases | 1 | 2012 | 80 | 0.080 |
Why?
|
| Surveys and Questionnaires | 3 | 2014 | 2789 | 0.080 |
Why?
|
| Adolescent | 2 | 2023 | 6350 | 0.070 |
Why?
|
| Aged | 3 | 2022 | 15089 | 0.070 |
Why?
|
| Hospitals, Urban | 1 | 2009 | 44 | 0.070 |
Why?
|
| Hospitals, University | 1 | 2009 | 57 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 733 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2014 | 2113 | 0.060 |
Why?
|
| Cromolyn Sodium | 1 | 2026 | 1 | 0.060 |
Why?
|
| Algorithms | 1 | 2012 | 1052 | 0.060 |
Why?
|
| Emergency Service, Hospital | 2 | 2018 | 1163 | 0.060 |
Why?
|
| Prospective Studies | 1 | 2012 | 3329 | 0.060 |
Why?
|
| Patient Discharge | 1 | 2009 | 521 | 0.050 |
Why?
|
| Administration, Sublingual | 1 | 2024 | 5 | 0.050 |
Why?
|
| Communication | 2 | 2018 | 606 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2023 | 63 | 0.050 |
Why?
|
| Child | 2 | 2023 | 4634 | 0.050 |
Why?
|
| Methadone | 1 | 2024 | 140 | 0.050 |
Why?
|
| Patient Care Team | 2 | 2009 | 337 | 0.050 |
Why?
|
| Montana | 1 | 2023 | 3 | 0.050 |
Why?
|
| Biomarkers | 2 | 2023 | 1487 | 0.050 |
Why?
|
| Farmers | 1 | 2023 | 20 | 0.050 |
Why?
|
| Dermatophagoides pteronyssinus | 1 | 2022 | 3 | 0.050 |
Why?
|
| Pyroglyphidae | 1 | 2022 | 7 | 0.050 |
Why?
|
| Desensitization, Immunologic | 1 | 2022 | 13 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2023 | 144 | 0.050 |
Why?
|
| Leptin | 1 | 2023 | 89 | 0.050 |
Why?
|
| Allergens | 1 | 2022 | 54 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2023 | 133 | 0.050 |
Why?
|
| Seasons | 1 | 2023 | 140 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 127 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2023 | 182 | 0.050 |
Why?
|
| Immunoglobulin E | 1 | 2022 | 81 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2023 | 381 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2014 | 757 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2023 | 323 | 0.040 |
Why?
|
| Nephrology | 1 | 2001 | 16 | 0.040 |
Why?
|
| Endocrinology | 1 | 2001 | 21 | 0.040 |
Why?
|
| Group Processes | 1 | 2001 | 42 | 0.040 |
Why?
|
| Curriculum | 1 | 2025 | 609 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2024 | 1026 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2025 | 762 | 0.040 |
Why?
|
| Interprofessional Relations | 1 | 2001 | 137 | 0.040 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2001 | 162 | 0.040 |
Why?
|
| Caregivers | 1 | 2023 | 298 | 0.040 |
Why?
|
| Rural Population | 1 | 2021 | 224 | 0.040 |
Why?
|
| Program Evaluation | 2 | 2017 | 498 | 0.040 |
Why?
|
| Diet | 1 | 2022 | 536 | 0.040 |
Why?
|
| Missouri | 1 | 2017 | 10 | 0.030 |
Why?
|
| Diagnostic Errors | 1 | 2018 | 106 | 0.030 |
Why?
|
| Infant | 1 | 2022 | 1711 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 807 | 0.030 |
Why?
|
| Health Policy | 1 | 2018 | 191 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2017 | 230 | 0.030 |
Why?
|
| Self Care | 1 | 2017 | 218 | 0.030 |
Why?
|
| Respiratory Sounds | 1 | 2015 | 21 | 0.030 |
Why?
|
| Evidence-Based Practice | 1 | 2015 | 86 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2018 | 445 | 0.030 |
Why?
|
| Rhode Island | 1 | 2015 | 110 | 0.030 |
Why?
|
| Dyspnea | 1 | 2015 | 120 | 0.030 |
Why?
|
| Chest Pain | 1 | 2015 | 86 | 0.030 |
Why?
|
| Fatigue | 1 | 2015 | 114 | 0.030 |
Why?
|
| New England | 1 | 2013 | 271 | 0.020 |
Why?
|
| Cough | 1 | 2015 | 183 | 0.020 |
Why?
|
| Intention | 1 | 2013 | 74 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2023 | 5820 | 0.020 |
Why?
|
| Purpura | 1 | 2012 | 3 | 0.020 |
Why?
|
| Dermatitis, Exfoliative | 1 | 2012 | 4 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2015 | 442 | 0.020 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2012 | 10 | 0.020 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2012 | 6 | 0.020 |
Why?
|
| Blister | 1 | 2012 | 15 | 0.020 |
Why?
|
| Physical Examination | 1 | 2012 | 109 | 0.020 |
Why?
|
| Psoriasis | 1 | 2012 | 59 | 0.020 |
Why?
|
| Soft Tissue Infections | 1 | 2012 | 48 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 931 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2014 | 744 | 0.020 |
Why?
|
| Social Support | 1 | 2013 | 394 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1273 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 992 | 0.020 |
Why?
|
| Cost Savings | 1 | 2009 | 60 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 2496 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2012 | 264 | 0.020 |
Why?
|
| Boston | 1 | 2009 | 260 | 0.020 |
Why?
|
| Neoplasms | 1 | 2018 | 1376 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 3777 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2009 | 489 | 0.010 |
Why?
|
| Animals | 1 | 2022 | 21459 | 0.010 |
Why?
|
| Hospitalization | 1 | 2009 | 1403 | 0.010 |
Why?
|